Article Details

INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Zacks Investment Research

Retrieved on: 2022-05-14 13:54:33

Tags for this article:

Click the tags to see associated articles and topics

INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Zacks Investment Research. View article details on hiswai:

Excerpt

According to Zacks, “INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up